FDA Acceptance of Zevra’s Arimoclomol NDA Filing for Niemann-Pick Disease Type C (NPC) Results in XOMA Making a $1 Million Milestone Payment to LadRx
11 janv. 2024 16h05 HE
|
XOMA Corporation
EMERYVILLE, Calif., Jan. 11, 2024 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA), the biotech royalty aggregator, announced today that based upon the U.S. Food and Drug Administration’s (FDA)...
Zevra Therapeutics Celebrates and Supports Global Niemann-Pick Disease Awareness Day on October 19th and Niemann-Pick Disease Awareness Month Throughout October
19 oct. 2023 07h30 HE
|
Zevra Therapeutics
CELEBRATION, Fla., Oct. 19, 2023 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA), a rare disease therapeutics company, proudly supports the Niemann-Pick community on Global...
ORPH FINAL DEADLINE ALERT: ROSEN, NATIONALLY REGARDED INVESTOR COUNSEL, Encourages Orphazyme A/S Investors with Losses to Secure Counsel Before Important September 7 Deadline in Securities Class Action – ORPH
05 sept. 2021 13h15 HE
|
The Rosen Law Firm PA
NEW YORK, Sept. 05, 2021 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Orphazyme A/S (NASDAQ: ORPH): (1) pursuant and/or...
ORPH BREAKING ALERT: ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Orphazyme A/S Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – ORPH
24 août 2021 17h45 HE
|
The Rosen Law Firm PA
NEW YORK, Aug. 24, 2021 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Orphazyme A/S (NASDAQ: ORPH): (1) pursuant and/or...
Orphazyme initiates rolling submission of New Drug Application for arimoclomol with US FDA in Niemann-Pick disease Type C
29 mai 2020 01h12 HE
|
ORPHAZYME A/S
Orphazyme A/SCompany announcement No....
Orphazyme announces US Early Access Program for Niemann-Pick disease Type C
06 janv. 2020 08h00 HE
|
ORPHAZYME A/S
Orphazyme A/SCompany announcement No....
Orphazyme reports positive arimoclomol data from open-label phase 2/3 extension in Niemann-Pick disease Type C
03 janv. 2020 01h00 HE
|
ORPHAZYME A/S
Orphazyme A/SCompany announcement No....
Orphazyme receives Breakthrough Therapy Designation for arimoclomol in Niemann-Pick Disease Type C (NPC)
19 nov. 2019 01h00 HE
|
ORPHAZYME A/S
Orphazyme A/SCompany announcement No....
Orphazyme to prepare for filing of arimoclomol in US for Niemann-Pick disease Type C (NPC)
21 juil. 2019 06h03 HE
|
ORPHAZYME A/S
Orphazyme A/SCompany announcement No. 18/2019Company Registration No. 32266355 ...
Orphazyme to prepare for filing of arimoclomol in Europe for Niemann-Pick disease Type C (NPC)
07 juin 2019 00h56 HE
|
ORPHAZYME A/S
Orphazyme A/SCompany announcement No....